Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma

Table 2 Percentage distribution (weighted for the sampling fraction) of treatment characteristics and survival for gastroesophageal adenocarcinoma patients diagnosed in 2001 NCI: Patterns of care study (n = 1356)¹ (Wt%)

	Lower esophagus		Gastric cardia		Stomach
	I-III	IV-V	I-III	IV-V	I-III	IV-V
Therapy received
Surgery only	12.3	1.3	34	2.2	49.6	15.7
Radiation only	8.1	3.5	4.7	7.2	2	3.3
Chemotherapy only	0.5	24	1.2	21.9	3.6	22.1
Surgery and radiation	0.8	0	2.6	0.9	3.9	0.4
Surgery and chemo	2.5	1.3	8.6	4.8	3.2	5.6
Surgery, rad, chemo	27	4.6	25	11.2	19.2	6.1
Chemo and radiation	36.5	46.8	9.8	12.4	1.5	3.4
None	12.4	18.7	14.1	39.4	17.1	43.4
Chemotherapy
No chemo	25.1	21.5	48.7	40.8	64.9	54.5
Single agent	5.4	25.5	11.4	9.9	10.3	8.4
Multi-agent	61.1	50.9	31.4	39.6	17.1	29
Refused	5.9	1.5	4.3	7.2	4	4.3
Rec, unknown if given	1.9	0	1	2.1	1.8	2.3
Unknown	0.6	0.6	3.2	0.4	2	1.5
Chemotherapy agent
5-FU	58.6	37.9	35.7	34.7	23.2	26.4
Doxorubicin	0.5	0	0.3	1	0.5	3.4
Capecitabine	1.2	0	0.7	7.4	0.6	4
Cisplatin	38.7	37.2	22	17.2	2.8	10.8
Etoposid	1	0	0.7	10.7	1.4	5.8
Irinotecan	0.7	12.9	0.5	5.9	1.6	5.6
Leucovorin	4.1	0.9	6.1	21.8	12.1	15.1
Mitomycin-C	13.	4.3	0.5	0.6	0.2	1.8
Oxaliplatin		No one
Epirubicin	0	0	0	1	0	1.2
Paclitaxel	11.8	20.8	5.9	7.3	2.2	4.6
Docetaxel	0	1.6	0.7	2.1	0.6	1.4
Chemotherapy plus surgery (with or without radiation)
No	70.5	94.2	68.3	84	77.7	87.8
Pre-op	23.7	4.9	16.8	6.4	0.3	0.5
Post-op	5.8	0.9	9	8.5	20.3	11.2
Unknown	0	0	5.9	1.1	1.7	0
Surgery plus chemotherapy and radiation
No	73	95.4	75	88.5	80.9	93.9
Pre-op	21.9	4.6	13.4	4.3	0.2	0.5
Post-op	5.1	0	8.6	6.9	17.4	5.6
Unknown	0	0	3	0	1.5	0
Median survival time (mo)
Non-surgical pts	13	8	8	6	5	4
Surgical patients	22	13	19	13	26	6

¹13 American Indians/Native Americans excluded.